Document is current
Any future updates will be listed below
-
Authors
Amamoo, James https://orcid.org/0009-0005-2785-0886
Doshi, Riddhi https://orcid.org/0000-0002-1439-1511
Noone, Joshua
Xie, Lin
Gamble, Cory https://orcid.org/0000-0001-9343-4761
Guevarra, Mico https://orcid.org/0009-0001-9381-4411
Divino, Victoria https://orcid.org/0000-0001-5555-7912
Chen, Justin https://orcid.org/0009-0002-7960-9697
King, Aaron
-
Funding
Funding for this research was provided by:
Novo Nordisk Inc.
- License Information
-
More Information
Article History
Received: 22 November 2024
Accepted: 28 February 2025
First Online: 27 March 2025
Declarations
:
: James Amamoo: Employee of Novo Nordisk Inc. Riddhi Doshi: Employee of IQVIA who received funding from Novo Nordisk Inc. to conduct this study. Joshua Noone: Employee of Novo Nordisk Inc. Lin Xie: Employee of Novo Nordisk Inc. Cory Gamble: Employee of Novo Nordisk Inc. and holds gifted stocks in Novo Nordisk. Mico Guevarra: Employee of Novo Nordisk Inc. and holds gifted stocks in Novo Nordisk. Victoria Divino: Employee of IQVIA who received funding from Novo Nordisk Inc. to conduct this study. New affiliation is Novo Nordisk Inc., Plainsboro, New Jersey, USA. Justin Chen: Employee of IQVIA who received funding from Novo Nordisk Inc. to conduct this study. Aaron King: Paid speaker and clinical advisor for Astellas Pharma, Abbott, Dexcom, Eli Lilly, Mannkind and Novo Nordisk Inc.
: The study involved use of IQVIA de-identified administrative claims and EMR data files. The Department of Health and Human Services does not consider analysis of deidentified secondary data to meet the definition for human subject research. Therefore, this study was exempt from federal regulations covering human subject research and did not require institutional review board review. This is as per exemption (d)4 from 45 CFR 46.104.
